These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24173089)

  • 1. Hepatitis B virus reactivation associated with ruxolitinib.
    Shen CH; Hwang CE; Chen YY; Chen CC
    Ann Hematol; 2014 Jun; 93(6):1075-6. PubMed ID: 24173089
    [No Abstract]   [Full Text] [Related]  

  • 2. Occult hepatitis B infection reactivation after ruxolitinib therapy.
    Perricone G; Vinci M; Pungolino E
    Dig Liver Dis; 2017 Jun; 49(6):719. PubMed ID: 28410914
    [No Abstract]   [Full Text] [Related]  

  • 3. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.
    Caocci G; Murgia F; Podda L; Solinas A; Atzeni S; La Nasa G
    Leukemia; 2014 Jan; 28(1):225-7. PubMed ID: 23929216
    [No Abstract]   [Full Text] [Related]  

  • 4. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.
    Chen YH; Lee CH; Pei SN
    Leuk Lymphoma; 2015 May; 56(5):1528-9. PubMed ID: 25213182
    [No Abstract]   [Full Text] [Related]  

  • 5. Telbivudine.
    Dienstag J; Easley C; Kirkpatrick P
    Nat Rev Drug Discov; 2007 Apr; 6(4):267-8. PubMed ID: 17458000
    [No Abstract]   [Full Text] [Related]  

  • 6. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
    Zhang MY; Zhu GQ; Zheng JN; Cheng Z; Van Poucke S; Shi KQ; Huang HH; Chen FY; Zheng MH
    Expert Rev Anti Infect Ther; 2017 May; 15(5):503-513. PubMed ID: 28317397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.
    Lee SC; Feenstra J; Georghiou PR
    BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24891492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib.
    Kirito K; Sakamoto M; Enomoto N
    Intern Med; 2016; 55(10):1341-4. PubMed ID: 27181544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma.
    Persico M; De Marino F; Russo GD; Morante A; Rotoli B; Torella R; De Renzo A
    Blood; 2002 Jan; 99(2):724-5. PubMed ID: 11799967
    [No Abstract]   [Full Text] [Related]  

  • 10. [Entecavir therapy against hepatitis B].
    Kato N; Omata M
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():340-4. PubMed ID: 15453342
    [No Abstract]   [Full Text] [Related]  

  • 11. Entecavir as prophylaxis against hepatitis B virus reactivation following chemotherapy for lymphoma.
    Uchiyama M; Tamai Y; Ikeda T
    Int J Infect Dis; 2010 Mar; 14(3):e265-6. PubMed ID: 19665406
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hepatitis B virus resistance to entecavir].
    Hidalgo-Tenorio C; Rivero M; Alvarez M; García F
    Med Clin (Barc); 2012 Jul; 139(5):228-9. PubMed ID: 22401720
    [No Abstract]   [Full Text] [Related]  

  • 13. Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure.
    Zhang Y; Hu XY; Zhong S; Yang F; Zhou TY; Chen G; Wang YY; Luo JX
    World J Gastroenterol; 2014 Apr; 20(16):4745-52. PubMed ID: 24782628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.
    Tseng CM; Chen TB; Hsu YC; Chang CY; Lin JT; Mo LR
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):421-429. PubMed ID: 27435683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients.
    Watanabe M; Shibuya A; Takada J; Tanaka Y; Okuwaki Y; Minamino T; Hidaka H; Nakazawa T; Koizumi W
    Eur J Intern Med; 2010 Aug; 21(4):333-7. PubMed ID: 20603047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.
    Molica S; Levato L; Mirabelli R; Tedeschi A; Lentini M
    Leuk Lymphoma; 2018 Nov; 59(11):2734-2736. PubMed ID: 29465275
    [No Abstract]   [Full Text] [Related]  

  • 17. [Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis].
    Xu Y; Wang JB; Xu J; Jiao J; Zhang YG; Ji SW; Zhao P; Guo HH; Li Y; Zhou CY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):109-12. PubMed ID: 20196949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of treatment with ruxolitinib in myelofibrosis.
    Tefferi A; Litzow MR; Pardanani A
    N Engl J Med; 2011 Oct; 365(15):1455-7. PubMed ID: 21995409
    [No Abstract]   [Full Text] [Related]  

  • 19. Epstein-Barr virus gastric ulcer associated with ruxolitinib.
    Kusano Y; Terui Y; Ueda K; Hatake K
    Ann Hematol; 2016 Oct; 95(10):1741-2. PubMed ID: 27411541
    [No Abstract]   [Full Text] [Related]  

  • 20. Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature.
    Santoro M; Rotolo C; Accurso V; Morreale I; Mancuso S; Siragusa S
    Chemotherapy; 2021; 66(3):87-91. PubMed ID: 33784668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.